Teriparatide
Also known as: PTH 1-34, PTH(1-34), rhPTH 1-34, recombinant human parathyroid hormone 1-34, Forteo
Anabolic bone agent; recombinant parathyroid hormone peptide fragment (amino acids 1–34)
What it is
Teriparatide is the active ingredient in Forteo, an FDA-approved injectable treatment for osteoporosis in people at high risk of bone fractures. It works by stimulating bone-building cells to add new bone tissue. Prescription-only; approved for osteoporosis; also studied for fracture healing and bone repair.
The scientific side
Teriparatide is the 1–34 amino-acid fragment of human parathyroid hormone (PTH). It binds to the PTH1 receptor (PTH1R) and, when administered intermittently, activates the Wnt signaling, cAMP/PKA, cAMP/PKC, and RANKL/RANK/OPG pathways, acting directly on mesenchymal stem cells, osteoblast-lineage cells, and osteocytes to promote bone formation. Intermittent dosing stimulates both remodeling-based bone formation (within active remodeling sites) and modeling-based bone formation (on previously inactive bone surfaces), yielding net increases in bone mineral density. Continuous administration, in contrast, promotes bone resorption rather than formation. In preclinical osteoarthritis models, teriparatide suppressed TNF-α–mediated MMP-13 overexpression, reducing synovial inflammation and cartilage degradation. In a rat cerebral ischemia model, teriparatide promoted angiogenesis via the AC/PKA signaling pathway, upregulating Ang-1 expression.
Class: Anabolic bone agent; recombinant parathyroid hormone peptide fragment (amino acids 1–34)
Administration & storage
- Administration
- Subcutaneous injection — daily (PMID: 35900607PMID: 27374026PMID: 40500389PMID: 36424580)Subcutaneous injection — weekly (PMID: 37529188PMID: 31429640)Subcutaneous continuous infusion via Omnipod® insulin pump device (PMID: 34984624)Thrice-daily subcutaneous injections — described in refractory hypoparathyroidism prior to pump use (PMID: 34984624)In vitro administration at 100 ng/mL in cell culture (PMID: 36371341)
- Storage
- Storage conditions for teriparatide are not described in the reviewed abstracts.
- Cautions
- Hypercalcemia has been reported with teriparatide use, including prolonged and severe cases (serum calcium >3.0 mmol/l); routine serum calcium monitoring during therapy is important, particularly in patients at risk (e.g., low body weight) (PMID: 40500389, PMID: 38613637).,Calciphylaxis (a rare, potentially fatal small-vessel occlusive disease) has been reported in association with teriparatide, predominantly in patients with multiple risk factors; median time-to-onset was 3.5 months after initiation.,Cardiac arrhythmias (including atrial tachycardia and atrial fibrillation) have been reported in teriparatide users based on pharmacovigilance data and case reports (PMID: 36543300, PMID: 29487102).,Teriparatide carries a warning (based on pre-approval animal studies) regarding an increased risk of osteosarcoma; its use is generally avoided in patients with risk factors for osteosarcoma, including prior radiotherapy.,Treatment discontinuation due to adverse events (including dizziness, hypercalcemia, elevated alkaline phosphatase, and arthralgia) appears more common with teriparatide than with bisphosphonates in some comparative studies (PMID: 38064598, PMID: 35900607).,BMD gains from teriparatide are not sustained after treatment discontinuation without subsequent antiresorptive therapy; less than half of patients in one real-world study received antiresorptive therapy after stopping teriparatide (PMID: 34490946, PMID: 29996965).,Sterile technique is essential for all injectable preparations to prevent infection at the injection site.
Legal & regulatory status
FDA-approved (Forteo) for postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, and for glucocorticoid-induced…
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Postmenopausal osteoporosis — fracture risk reduction and BMD improvement Human RCT
- Full 24-month daily teriparatide course increases bone formation and reduces fracture risk; anti-fracture efficacy appears to increase with longer duration of therapy. PMID 26902094 Lindsay R et al. Osteoporosis Int (2016)
- Meta-analysis (14 RCTs): teriparatide associated with lower total vertebral fractures (RR=0.55, 95% CI 0.40–0.77) and nonvertebral fractures (RR=0.65, 95% CI 0.46–0.90) vs. bisphosphonates; improved BMD at lumbar spine and femoral neck. PMID 32282692 Fan G et al. Medicine (2020)
- Meta-analysis: teriparatide reduced vertebral fracture risk vs. bisphosphonates (RR=0.57, 95% CI 0.35–0.93); increased BMD in lumbar spine at 6, 12, and 18 months. PMID 30890377 Yuan F et al. Int J Surg (2019)
- Generic teriparatide 20 µg SC daily noninferior to alendronate 70 mg oral weekly for lumbar spine BMD change at 48 weeks in Chinese postmenopausal women; adverse events including hypercalcemia, dizziness, and arthralgia more common with teriparatide. PMID 35900607 Li M et al. Arch Osteoporos (2022)
- 10-year follow-up after mean 18 months teriparatide 20 µg SC daily: fracture prevalence decreased from 100% to 35% (p<0.0001), comparable to general population levels; BMD gains did not persist after treatment cessation. PMID 36424580 Kontogeorgos G et al. BMC Musculoskelet Disord (2022)
- Meta-analysis (5 RCTs, 3376 participants): teriparatide reduced clinical vertebral fracture (OR=1.97) and new vertebral fractures (OR=2.44) vs. bisphosphonates; higher rate of dizziness and treatment discontinuation due to adverse events with teriparatide. PMID 38064598 Zhong Q et al. Altern Ther Health Med (2024)
- Glucocorticoid-induced osteoporosis — BMD improvement and fracture prevention Human RCT
- Meta-analysis (10 studies, 2923 patients): teriparatide superior to bisphosphonates in lumbar vertebral BMD (MD 3.98%, 95% CI 3.61–4.175%), vertebral fracture prevention, and hip BMD in glucocorticoid-using patients. PMID 37349750 Yuan C et al. J Orthop Surg Res (2023)
- Meta-analysis: teriparatide increased BMD at lumbar spine, femoral neck, and total hip more than bisphosphonates; GIO subgroup showed larger BMD gains and lower vertebral fracture risk vs. bisphosphonates. PMID 28653616 Liu CL et al. Clin Invest Med (2017)
- Fracture healing (general, hip, pertrochanteric, nonunion) Mixed
- RCT (50 participants): daily teriparatide for 12 weeks after pertrochanteric fracture fixation significantly shortened radiographic bone union time (7.44 vs. 10.56 weeks, p=0.0083); no significant differences in clinical outcomes between groups. PMID 40461584 Tanavalee C et al. Sci Rep (2025)
- Double-blind RCT: weekly teriparatide improved RUSH scores at 3 months (15.476 vs. 12.105, p=0.004) and 6 months (22.389 vs. 18.571, p=0.006) in hip fracture patients; lumbar BMD increased >7% at 1 year in teriparatide group. PMID 37529188 Lee SY et al. Clin Orthop Surg (2023)
- Meta-analysis (5 RCTs, 380 patients): teriparatide showed significant functional improvement after fracture, but no significant benefit for time to radiographic healing, healing rate, or pain reduction; no apparent increase in adverse effects. PMID 27997614 Shi Z et al. PLoS One (2016)
- Retrospective study (59 complete atypical femur fractures): no significant difference in time-to-bone union between teriparatide and non-teriparatide groups (5.8 vs. 5.5 months, p=0.359). PMID 38907093 Song G et al. Calcif Tissue Int (2024)
- Pilot RCT (13 women, AFF): trend for superior healing composite score and lesser BMD decline at 1/3 distal radius with immediate vs. delayed teriparatide; no differences in adverse events. PMID 29085957 Greenspan SL et al. Osteoporos Int (2018)
- Spinal fusion surgery in osteoporotic patients — improving fusion rates and outcomes Mixed
- Meta-analysis (12 studies, 771 patients): teriparatide significantly higher lumbar spinal fusion rates vs. non-teriparatide group (OR 2.15, 95% CI 1.56–2.97); also reduced subsequent vertebral fractures and VAS scores. PMID 32728969 Fatima N et al. Neurosurg Rev (2021)
- Systematic review/meta-analysis (19 studies): bisphosphonates associated with higher fusion rate (ES 83%) than teriparatide (ES 71%), without statistical significance (p=0.123); teriparatide associated with lower screw loosening rate. PMID 33030619 Tsai SHL et al. Arch Osteoporos (2020)
- RCT (64 osteoporotic patients undergoing adult spinal deformity surgery): perioperative teriparatide (3 months pre- to 3 months postoperatively) significantly reduced proximal junctional failure vs. denosumab (3.4% vs. 22.2%, p=0.034) and improved back pain and EQ-5D. PMID 40100350 Park JH et al. Osteoporos Int (2025)
- Premenopausal idiopathic osteoporosis — bone microstructure improvement Human RCT
- Phase 2B RCT: teriparatide 20 mcg daily (up to 24 months) followed by denosumab 60 mg q6M (24 months) in premenopausal idiopathic osteoporosis; sequential treatment improved tibial and radial vBMD, trabecular microarchitecture, cortical thickness, and whole-bone strength at 48 months. PMID 36335582 Agarwal S et al. J Bone Miner Res (2023)
- Hypoparathyroidism (PTH replacement) Mixed
- Systematic review/meta-analysis (18 studies, 94 pediatric patients): teriparatide maintained serum calcium and lowered serum phosphate (WMD -0.28, 95% CI -0.45 to -0.12) vs. conventional therapy in children with hypoparathyroidism; conventional therapy remains first-line. PMID 42501079 Tantivit N et al. Calcif Tissue Int (2026)
- Two cases of refractory postsurgical hypoparathyroidism: continuous SC infusion of teriparatide via Omnipod® pump (average doses 23 and 32 mcg/day) normalized calcemia and allowed calcium/vitamin D withdrawal after failure of thrice-daily SC injections. PMID 34984624 Aouchiche K et al. Endocrine (2022)
- Medication-related osteonecrosis of the jaw (MRONJ) Mixed
- Systematic narrative review: clinical studies suggest intermittent teriparatide may benefit therapy-resistant MRONJ; more RCTs needed to confirm efficacy and safety. PMID 37695713 Gera I, Szücs N. Orv Hetil (2023)
- Case report: MRONJ around dental implant in 85-year-old woman successfully managed with once-weekly teriparatide without surgical intervention. PMID 31429640 Kim JY et al. J Oral Implantol (2019)
- Osteoarthritis — cartilage and subchondral bone protection Animal studies only
- Systematic review (33 studies): in vivo studies showed PTH(1-34) slowed OA progression by alleviating cartilage degeneration and subchondral bone remodeling; in vitro studies showed increased chondrocyte proliferation and matrix synthesis; no approved human use. PMID 36609338 Li G et al. Arthritis Res Ther (2023)
- Mouse DMM model: teriparatide prevented synovitis and cartilage degradation by suppressing TNF-α–mediated MMP-13 overexpression. PMID 36537662 Liang X et al. Connect Tissue Res (2023)
- Osteoporosis in patients with type 2 diabetes Human observational
- Post hoc analysis of DANCE observational study (4042 patients, 291 with T2D): teriparatide 20 µg/day SC up to 24 months reduced nonvertebral fracture incidence, increased BMD, and decreased back pain similarly in T2D and non-diabetic patients; well tolerated with no new safety findings. PMID 27374026 Schwartz AV et al. Bone (2016)
- Cerebral ischemia-reperfusion injury — neuroprotection (preclinical only) Animal studies only
- Rat middle cerebral artery occlusion model: teriparatide promoted angiogenesis via AC/PKA signaling, reduced cerebral infarct size, inhibited neuroinflammation, and protected the blood-brain barrier. PMID 35220030 Xiong M et al. Biomed Pharmacother (2022)
- Adult hypophosphatasia — fracture healing support Mixed
- Case series (2 patients) with literature review of 6 additional patients: daily teriparatide injections showed some benefit for bone pain and consolidation in adult HPP; alkaline phosphatase increased during treatment; BMD changes were variable. PMID 27042741 Camacho PM et al. Endocr Pract (2016)
Safety signals
- Hypercalcemia (transient, occurring in up to 11% of patients; delayed and prolonged cases also reported) PMID 38613637
- Prolonged asymptomatic hypercalcemia in a low BMI patient on standard 20 mcg daily dose; calcium normalized after discontinuation PMID 40500389
- Calciphylaxis (rare, potentially fatal; 12 cases reported postmarketing; median onset 3.5 months; associated with multiple underlying risk factors) PMID 34494145
- Atrial tachycardia temporally coinciding with teriparatide injections (single case report) PMID 29487102
- Pharmacovigilance association with atrial fibrillation, cardiac arrhythmias, and angina pectoris (disproportionality analysis of WHO Vigibase reports) PMID 36543300
- Elevation of transaminases (hypertransaminasemia) possibly associated with teriparatide; causality classified as 'possible' PMID 33199399
- Higher rate of dizziness vs. bisphosphonates in meta-analysis of postmenopausal osteoporosis RCTs PMID 38064598
- Adverse events including hypercalcemia, elevated alkaline phosphatase or PTH, dizziness, and arthralgia more common than with alendronate in a Chinese RCT PMID 35900607
- Osteosarcoma risk warning based on pre-approval animal studies; follow-up of treated individuals has not confirmed increased risk in humans but caution recommended in patients with radiotherapy history PMID 34608566
- BMD loss following teriparatide discontinuation without antiresorptive follow-on therapy; switching from denosumab to teriparatide results in progressive or transient bone loss PMID 26144908
- Suboptimal persistence/adherence: median teriparatide use 7.2 months in Medicare population; 365-day discontinuation rate 70.9% in Japanese elderly patients PMID 34490946
- Older age, initiation during hospitalization, and side effects were risk factors negatively influencing weekly teriparatide continuation PMID 31583539
Protocol
Teriparatide is an approved clinical compound used medically, not as a research peptide. For medical use, see a doctor.
All studies (41)
- PMID 26902094 Human RCT
Postmenopausal osteoporosis — fracture risk reduction and BMD improvement - PMID 28653616 Human RCT
Glucocorticoid-induced osteoporosis — BMD improvement and fracture prevention - PMID 30890377 Human RCT
Postmenopausal osteoporosis — fracture risk reduction and BMD improvement - PMID 32282692 Human RCT
Postmenopausal osteoporosis — fracture risk reduction and BMD improvement - PMID 35900607 Human RCT
Postmenopausal osteoporosis — fracture risk reduction and BMD improvement - PMID 36335582 Human RCT
Premenopausal idiopathic osteoporosis — bone microstructure improvement - PMID 36424580 Human RCT
Postmenopausal osteoporosis — fracture risk reduction and BMD improvement - PMID 37349750 Human RCT
Glucocorticoid-induced osteoporosis — BMD improvement and fracture prevention - PMID 38064598 Human RCT
Postmenopausal osteoporosis — fracture risk reduction and BMD improvement - PMID 27374026 Human observational
Osteoporosis in patients with type 2 diabetes - PMID 27042741 Mixed
Adult hypophosphatasia — fracture healing support - PMID 27997614 Mixed
Fracture healing (general, hip, pertrochanteric, nonunion) - PMID 29085957 Mixed
Fracture healing (general, hip, pertrochanteric, nonunion) - PMID 31429640 Mixed
Medication-related osteonecrosis of the jaw (MRONJ) - PMID 32728969 Mixed
Spinal fusion surgery in osteoporotic patients — improving fusion rates and outcomes - PMID 33030619 Mixed
Spinal fusion surgery in osteoporotic patients — improving fusion rates and outcomes - PMID 34984624 Mixed
Hypoparathyroidism (PTH replacement) - PMID 37529188 Mixed
Fracture healing (general, hip, pertrochanteric, nonunion) - PMID 37695713 Mixed
Medication-related osteonecrosis of the jaw (MRONJ) - PMID 38907093 Mixed
Fracture healing (general, hip, pertrochanteric, nonunion) - PMID 40100350 Mixed
Spinal fusion surgery in osteoporotic patients — improving fusion rates and outcomes - PMID 40461584 Mixed
Fracture healing (general, hip, pertrochanteric, nonunion) - PMID 42501079 Mixed
Hypoparathyroidism (PTH replacement) - PMID 26144908
20 mg daily (teriparatide arm) Not specified (human) - PMID 29487102
Atrial tachycardia temporally coinciding with teriparatide injections (single case report) - PMID 29996965
- PMID 31583539
Older age, initiation during hospitalization, and side effects were risk factors negatively influencing weekly teriparatide continuation - PMID 33199399
Elevation of transaminases (hypertransaminasemia) possibly associated with teriparatide; causality classified as 'possible' - PMID 34224692
- PMID 34490946
Suboptimal persistence/adherence: median teriparatide use 7.2 months in Medicare population; 365-day discontinuation rate 70.9% in Japanese elderly patients - PMID 34494145
Calciphylaxis (rare, potentially fatal; 12 cases reported postmarketing; median onset 3.5 months; associated with multiple underlying risk factors) - PMID 34608566
Osteosarcoma risk warning based on pre-approval animal studies; follow-up of treated individuals has not confirmed increased risk in humans but caution recommen - PMID 35220030 Animal studies only
Cerebral ischemia-reperfusion injury — neuroprotection (preclinical only) - PMID 35797582
4-month preoperative course (dose not specified) Not specified (human) - PMID 36371341
100 ng/mL In vitro (cell culture medium) (in_vitro) - PMID 36537662 Animal studies only
Osteoarthritis — cartilage and subchondral bone protection - PMID 36543300
Pharmacovigilance association with atrial fibrillation, cardiac arrhythmias, and angina pectoris (disproportionality analysis of WHO Vigibase reports) - PMID 36609338 Animal studies only
Osteoarthritis — cartilage and subchondral bone protection - PMID 37606211
20 mcg daily (subcutaneous) Subcutaneous injection (human) - PMID 38613637
Hypercalcemia (transient, occurring in up to 11% of patients; delayed and prolonged cases also reported) - PMID 40500389
20 mcg daily (standard dose) Subcutaneous injection (human)